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Aldicarb, the active ingredient in the insecticide TEMIK, was introduced to the agricultural community over 25 years ago. It has been registered
worldwide to control a wide variety of insect, mite, and nematode pests in agriculture. The toxicological research database supporting the registra-
tion and use of aldicarb was generated over more than 25 years and contains more than 280 animal studies on 12 species of animals, 2 clinical
human trials, and over 20 human monitoring studies. This database, which includes biochemical aspects (metabolism and mode-of-action studies),
acute toxicity and special short-term toxicity studies, long-term toxicity studies, and epidemiological observations in humans, serves as the starting
point for the evaluation of the risks associated with the acceptance of levels of aldicarb residues in food and drinking water and for the more direct
occupational exposure. This article highlights the available toxicological data and reviews worldwide regulation of aldicarb. Included in these discus-
sions is a brief description of the toxicological end point upon which regulatory decisions have been based, namely acetylcholinesterase depression.
Aldicarb, the N-methylcarbamic acid ester of 2-methyl-2-(methylthio) propionaldehyde oxime, was the first of a limited group of insecticidal oxime N-
methylcarbamates that have properties distinct from N-methylcarbamates which have a phenolic constituent, instead of the oxime moiety. Aldicarb
is highly water-soluble (approximately 6000 ppm), nonvolatile, relatively stable under acidic conditions, and is easily degraded under alkaline condi-
tions. These properties are important determinants of its systemic action in plants and of its problematic environmental behavior. Possible environ-
mental hazards involving the chemical include groundwater contamination and (more recently) excessive terminal residues in certain foods.
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Mammalian Toxicology
The toxicology database contains more
than 280 animal studies on 12 species of
animals, 2 clinical human trials and over 20
human monitoring studies (1,2). The signs
and symptoms of acute aldicarb-poisoning
are characteristic of that of other organo-
phosphorus and carbamate insecticides.
Poisoning results primarily from nicotinic
and parasympathetic effects produced by
inhibition of acetylcholinesterase in the
peripheral somatic and autonomic nervous
systems. The effects of acute overexposure
to aldicarb and aldicarb metabolites are
transient in nature, primarily because of
rapid spontaneous recovery of the car-
bamoylated (inhibited) acetylcholinesterase
and a swift rate ofdistribution and metabo-
lism and excretion from the body.
Complete recovery typically occurs within
3 to 6 hr of exposure. Aldicarb, like all
cholinergic N,N-dimethyl, N-methylcarba-
mate, and organophosphate insecticides,
exerts its neurotoxic effects through inhibit-
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ing acetylcholinesterase in nerve synapses
and myoneural junctions. Acetylcholin-
esterase inhibition by these insecticides
involves the formation of an enzyme-
inhibitor complex followed by the reaction
of this inhibitor at the active site of the
enzyme, which generates either a carbamoy-
lated or phosphorylated enzyme. Phos-
phorylated acetylcholinesterase is relatively
stable, so that inhibition is virtually irre-
versible after a phenomenon defined as
aging has occurred. However, carbamoy-
lated acetylcholinesterase can be readily,
and spontaneously hydrolyzed to regenerate
the original form of the active enzyme.
Although the carbamoylated enzyme is
sufficiently stable to disrupt cholinergic
transmission, acetylcholinesterase activity is
rapidly regenerated following subacute
doses. Repeated subacute dosing with
cholinergic N-methylcarbamate insecticides
does not lead to cumulative intoxication,
based on what is known about the insecti-
cides' mode ofaction and the general physi-
cochemical properties ofthe chemical class.
While not being readily defined in
pharmacokinetic terms, the qualitative and
quantitative metabolic pattern ofdegrada-
tion in plants and animals is well known.
Aldicarb is quickly oxidized to aldicarb sul-
foxide and more slowly to aldicarb sulfone,
before undergoing hydrolytic breakdown
to noncholinergic agents. Aldicarb sulfox-
ide is a more potent inhibitor of acetyl-
cholinesterase than is aldicarb itself, but
aldicarb sulfone is less active than aldicarb,
the original sulfide. These inhibitory rela-
tionships generally agree with the acute
mammalian toxicity relationships observed
with aldicarb and its metabolites.
Considerable evidence supports the
view that the toxicological responses of
humans to aldicarb and its metabolites are
similar or identical to those oflaboratory
animals. Aldicarb has a high acute mam-
malian toxicity (LD50=0.3-1.5 mg/kg) fol-
lowing oral or parenteral administration to
laboratory animals. Dermal toxicity is also
high (rabbit dermal LD50 -5 mg/kg), but is
dependent on the administration vehicle
used. The acute mammalian toxicity of
aldicarb sulfoxide is similar to aldicarb;
whereas that of aldicarb sulfone is lower
(LD50 - 20-25 mg/kg). Acute studies show
that aldicarb is not an eye or skin irritant
and does not induce a dermal-contact sensi-
tization response. In a significant array of in
vivo and in vitro bioassays, aldicarb has
been shown to be nonresponsive to all mea-
sured immunological parameters.
Multigeneration animal reproduction stud-
ies show no adverse reproductive effects; no
developmental effects were noted in teratol-
ogy studies. Dominant lethal studies were
also negative. Although the highest dose
level tested (1 mg/kg) approximated the
acute oral LD50value, no significant effects
were found by any of the measurements
associated with fertility, gestation, viability,
or lactation. There was no evidence ofcon-
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genital malformation in any ofthe treated
groups. There have been several reports of
aldicarb causing a depression offetal blood
and brain acetylcholinesterase activity
(3-5). This was shown in rats when
aldicarb was administered on day 18 ofges-
tation and fetal tissues monitored soon
thereafter. Although statistical significance
was reported with respect to the treated and
control group comparisons, the levels of
depression concomitant of 12 and 18% for
fetal blood and brain, respectively, were not
associated with toxic signs or resulting
pathology. As multigeneration reproduction
studies examining behavior in rodent pups
derived from aldicarb- and aldicarb metabo-
lite-exposed mothers have been consistently
negative, it is difficult to imagine a long-
term or residual effect following in utero
exposure, irrespective ofslight degree of
acetylcholinesterase depression measured in
fetal tissue.
Genetic toxicity studies (mutagenesis)
in rats were negative, as demonstrated in an
array ofshort-term bioassays. Aldicarb has
been tested for carcinogenicity and shown
to be negative in several in vivo model
bioassay systems using a variety ofadminis-
tration routes, including oral and dermal.
Other than intermittent inhibition of
acetylcholinesterase (an acute effect), there
has been no evidence that aldicarb or its
metabolites display any adverse chronic
effects when administered to rats or mice
in lifetime studies.
In a preliminary 14-day range-finding
study in dogs (NN Hamanda, unpublished
data), acetylcholinesterase inhibition was
noted at doses exceeding 0.1 mg/kg. A 1-
year study in dogs (NN Hamada unpub-
lished data) was designed to produce
maximal acetylcholinesterase depression by
limiting feeding time to 2 hr/day to mimic
a bolus administration ofaldicarb, and also
by using rapid analyses (within 4 hr of
feeding) oferythrocyte and plasma acetyl-
cholinesterase levels under analytical condi-
tions that minimize dissociation of the
carbamate-acetylcholinesterase complex.
Aldicarb exposure, at doses up to 0.235
mg/kg, resulted in no observable adverse
effects other than transient inhibition of
erythrocyte and plasma acetylcholinesterase
activity. The no-effect level for acetyl-
cholinesterase inhibition was 0.025 mg/kg.
Human Studies
The availability of direct observations on
the toxicity of aldicarb (or for that matter
any chemical) to human subjects reduces
some of the uncertainty inherent in the
extrapolation to humans of the results
observed with laboratory animals. A con-
siderable database exists on the acute, sub-
chronic, and chronic effects ofaldicarb and
its metabolites on several species oflabora-
tory animals (rats, mice, guinea pigs, dogs,
primates, and rabbits) as well as humans.
These reports have served as the basis of
several risk assessments by the U.S.
Environmental Protection Agency (U.S.
EPA) (6), the Safe Drinking Water
Committee of the National Academy of
Sciences' National Research Council
(SDWC/NAS/NRC) (7-10), by Cornell
University (CF Wilkinson, unpublished
data), and by the Food and Agricultural
Organization (FAO) and World Health
Organization (WHO) Joint Meeting on
Pesticide Residues UMPR) (11-13).
Studies examining the acute effects of
aldicarb administered orally to human vol-
unteers show the same pattern of rapid
acetylcholinesterase inhibition and rapid
recovery seen in experimental animal mod-
els (NN Hamada, unpublished data). In
human subjects following two preliminary
analyses ofblood acetylcholinesterase activ-
ity, groups consisting of four adult male
volunteers each were given aqueous solu-
tions of aldicarb at acute oral doses of
0.025, 0.05, or 0.1 mg/kg; in a similar
trial, two subjects were given doses of0.05
or 0.26 mg/kg (1,2,13). In both trials,
individuals were monitored prior to
aldicarb exposure and served as their own
controls. Observation for signs ofpoison-
ing and measurements ofwhole-blood
acetylcholinesterase activity was made for 6
hr following treatment. As this is one ofthe
most meaningful studies in defining an
acute human response to aldicarb exposure,
the data from the larger trial are presented
in Table 1.
Acute cholinergic signs and symptoms
ofoverexposure were observed only in sub-
jects exposed to a dose of 0.1 mg/kg or
higher. Clinical signs ofoverexposure were
not noted at doses of0.05 mg/kg or lower.
By 6 hr after administration, acetyl-
cholinesterase activity had returned to nor-
mal, and clinical cholinergic signs and
symptoms had disappeared with no med-
ical treatment. A dose-related depression
from pre-trial values ofwhole blood acetyl-
cholinesterase was observed in all individu-
als, mainly 1 to 2 hr after exposure.
A second clinical trial was reported in
1992 by the manufacturer Rhone Poulenc
Ag Company and reviewed by the JMPR
(2). These unpublished data were gener-
ated by Inveresk Clinical Research,
Edinburgh, Scotland, as ICR Project
003237, March 11, 1992.
There are several advantages to using
these human exposure data for regulatory
risk assessment. first, the study describes
the time course of whole blood acetyl-
cholinesterase depression and recovery,
allowing the development ofmathematical
models to describe the degree and duration
ofacetylcholinesterase depression (whole
blood acetylcholinesterase activity is to a
great extent composed of red blood cell
acetylcholinesterase activity). Second, since
the data were obtained from humans, there
is little need for an interspecies extrapola-
tion factor, as is typical for risk assessments
where animal data provide the sole basis for
human risk assessment. Last, the condi-
tions ofexposure used probably represent a
worst case situation, since the bioavailabil-
ity ofaldicarb is almost surely greatest from
a single bolus ingestion ofan aqueous solu-
tion. In 1986, the SDWC/NAS/NRC
intensively examined the data from the
human study using a statistical model to
Table 1. Symptomatology and effects on whole-blood acetylcholinesterase in human volunteers.
Body Aldicarb Blood acetylcholinesterase levelsa
Subject weight, ingested Predose, hr Postdose, hr
number kg mg mg/kg 18 1 1 2 4 6 Symptoms
1 94.5 9.5 0.1 167 85 58 68 107 123 Yesb
2 86.5 8.7 0.1 149 112 69 45 83 119 Yesb
3 82.5 8.3 0.1 218 185 57 47 84 120 Yes
4 65.0 6.6 0.1 176 175 55 35 120 149 Yesb
5 97.5 4.0 0.05 129 191 77 93 139 152 No
6 87.0 4.4 0.05 171 159 64 62 136 134 ?-Noc
7 77.5 3.0 0.05 168 155 50 97 142 152 No
8 71.5 3.6 0.05 210 171 100 81 156 172 No
9 92.5 2.3 0.025 194 225 122 131 168 205 No
10 82.5 2.1 0.025 163 191 82 85 140 146 No
11 79.5 2.0 0.025 147 74 100 154 135 No
12 89.5 2.2 0.025 143 94 100 132 140 No
'Observed hydrolysis rate ofacetylcholine (pm/hr/mI).
bPresent in first 2 hr after ingestion; none visible after 4
hr.cPossible symptom in first hour; none thereafter.
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Table 2. Maximum inhibition of cholinesterase as
specified by SDWC/NAS/NRC.
Dose, mg/kg Mean inhibition, %
0.100 73
0.50 64
0.025 47
Table 3. Projected cholinesterase depression at lower
dose levels by SDWC/NAS/NRC.
Dose, mg/kg Mean inhibition, %
0.01 30
0.005 20
project the acetylcholinesterase depression
response to low exposure levels (10). To
reflect maximal inhibition, calculations
were based on each individual's highest
pretrial values and maximum depression at
either 1 or 2 hr after administration. Table
2 shows the mean maximum depression
reported by the Committee.
Whole-blood acetylcholinesterase
depression was on the order of > 60%
without clinical signs of overexposure, as
seen in the mid- and low-dose groups.
The Committee's model, which consid-
ered the most conservative control acetyl-
cholinesterase activity values and the
maximum acetylcholinesterase depression
values, using probit and logit regression
analyses ofthese data, projected the enzyme
depression at lower doses (Table 3).
To explore the inherent safety to
humans of an acceptable daily intake of
aldicarb residues of 0.005 mg/kg,
cynomolgus monkeys were fed bananas
and watermelon containing actual terminal
residues resulting from aldicarb treatment
UA Trutter, unpublished data). The assess-
ment by the SDWC/NAS/NRC suggested
that an intake of 0.005 mg/kg ofaldicarb
residues would produce no overt signs of
toxicity, but would induce a short-term
low-level depression of blood acetyl-
cholinesterase activity. The aim ofthe pri-
mate study was to confirm the safety of
ingesting residues this size.
Bananas and watermelons were treated
with aldicarb at exaggerated schedules to
assure adequate residues in the fruit.
Following analytical determination of
actual residues in the two commodities to
be consumed, intake of the treated crop
was adjusted with control fruit to provide a
dose ofexactly 0.005 mg/kg. The animals
were offered the fruit as the first meal of
the day, and they consumed it immedi-
ately. Individuals were monitored for clini-
cal signs, and plasma and erythrocyte
acetylcholinesterase activities were mea-
sured periodically for 24 hr after feeding.
With both commodities, fed individually
in two independent trials, there was no
sign of acute cholinergic distress or any
signs of overexposure in any animal.
Depression ofplasma acetylcholinesterase
activity was evident within 1 to 4 hr after
ingestion and reached a maximum of35%.
Erythrocyte acetylcholinesterase activity
was not depressed. As expected, rapid
recovery of all enzyme activity was
observed, agreeing with prior observations
of aldicarb-induced acetylcholinesterase
depression and recovery in human volun-
teer studies. Acetylcholinesterase depres-
sion in humans and nonhuman primates
was similar with respect to onset, duration,
magnitude, time of recovery, and absence
ofadverse signs ofcholinergic distress. It
was concluded that acute ingestion of
residues by humans to an acceptable daily
intake (ADI) value of0.005 mg/kg would
be toxicologically insignificant.
Regulatory Assessments
The no-observable-effect-level (NOEL) of
a material is considered to be the daily dose
that produces no sign oftoxicity in a popu-
lation of test animals (or humans) and is
usually derived from the results of long-
term toxicity studies. Although the NOEL
does not refer specifically to a toxic effect,
it obviously implies that the monitored
effect is of an adverse nature and, without
proofto the contrary, it is often assumed
any biological effect resulting from expo-
sure to a chemical is of real or potential
toxicological meaning. In recent years, reg-
ulatory authorities have begun using the
acronym NOAEL (no-observable-adverse-
effect-level), but generally tend to use some
of the same effects as end points for risk
assessments. Usually, NOEL values are
established from dose-response data gotten
with any species of laboratory animals
(rats, mice, dogs, etc.). When human data
are available they usually take precedence
over animal data, although human trials
often involve few replicates and cover short
experimental periods. Where human data
are not available, human sensitivity is usu-
ally assumed to be that of the most sensi-
tive animal species.
In defining safety to humans, an uncer-
tainty factor is generally applied in the risk
assessment. This takes into consideration
the degree of uncertainty in extrapolation
of animal data to the human experience
and to reflect the variability within the
human population itself. When one
ascribes to the safety factor mechanism for
regulatory risk assessment, and good qual-
ity toxicological data are available with dif-
ferent animal species showing a fairly
uniform species response, a relatively low
safety margin can be applied. This is par-
ticularly true ifappropriate human data are
available and doubly so ifthe effect is read-
ily reversible. The safety factor may need to
be greater ifthe available data are question-
able, where few species have been studied,
and particularly, where no human data are
available. In short, the magnitude of the
safety factor employed is determined by
the adequacy of the database; it is a
reflection ofthe degree ofuncertainty asso-
ciated with the data.
Extrapolation ofthe maximum dietary
level causing no adverse effects in experi-
mental animals to the establishment ofan
average daily intake (ADI, also known as
the reference dose [RfD] by the U.S.EPA)
for humans typically involves the use ofan
arbitrary uncertainty or safety factor. A
safety factor of 100 has been widely
accepted historically, although this may be
increased or decreased depending on the
amount and types of toxicological data
upon which the assessment is based.
According to a 1977 SDWC/NAS/NRC
report "Drinking Water and Health" (7)
the following guidelines have been adopted
and been reaffirmed several times: a) A
safety factor of 10 may be applied when
valid experimental data from studies on
prolonged ingestion by man are available,
and where there is no evidence of carcino-
genicity. b) A safety factor of 100 may be
applied in cases where data on prolonged
human studies are not available or are
scanty (e.g., only acute exposures), where
valid results on long-term animal feeding
studies are available with several species,
and where there is no evidence ofcarcino-
genicity. c) An uncertainty factor of 1000
should be applied where there are no long-
term or acute human data, where animal
data are scanty, and where there is no evi-
dence ofcarcinogenicity.
These are also the general guidelines that
have been followed by the FAO/WHO's
JMPR in establishingacceptable daily intake
values for residues ofpesticides and their
metabolites.
Regulatory History
A considerable database exists defining the
acute, subchronic, and chronic effects of
aldicarb and its metabolites on several
species oflaboratory animals (rats, mice,
guinea pigs, dogs, primates, and rabbits)
and on humans. These data have been used
extensively to address regulatory require-
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Table 4. Chronological regulatory history.
Year Source ADI, mg/kg bw
1969 FDA 0.001
1970s U.S.EPA-OPP 0.003
1977, '80,'83 SDWC/NAS/NRC 0.001
1979 JMPR 0.001
1981 U.S.EPA-OPP 0.003
1982 JMPR 0.005
1983 Cornell University 0.003-0.01
1986 SDWC/NAS/NRC 0.001
1986 U.S.EPA-ODW/OPP 0.001
1990 U.S.EPA-ODW/OPP 0.0002
1992 JMPR
ments. A briefhistory ofthe resulting regu-
latory activities associated with aldicarb is
presented in Table 4 using the health stan-
dard, the ADI (now U.S.EPA's RfD), as
the basis for discussion.
The U.S. Food and DrugAdministration
(FDA) (preceding U.S.EPA's formation)
first assessed safety ofaldicarb and issued
crop tolerances for aldicarb residues in
1969. Over the first decade ofits registered
life, a generally accepted NOEL of 0.125
mg/kg bw/day for aldicarb and its metabo-
lites (primarily the sulfoxide) was based
mainly on observed levels of acetyl-
cholinesterase depression in rat studies.
The first ADI was established at 0.001
mg/kg. During the 1970s, the ADI was
increased to 0.003 mg/kg, based on data
from newer studies with rats.
In 1977, the SDWC/NAS/NRC (7),
while stating that "it is not likely that
[aldicarb] will appear as a major contami-
nant in drinking water," defined a NOEL
of 0.1 mg/kg from studies with rats and
dogs. Using a safety factor of 100, the com-
mittee recommended an ADI of 0.001
mg/kg. In later evaluations (in 1980, 1983,
1986) this committee reaffirmed its initial
recommendation despite using different
criteria (11).
In 1979, the JMPR applying a safety
factor of about 100 to a NOEL of 0.125
mg/kg recommended an ADI for humans
of0.001 mg/kg (12).
In 1981, the EPA reconfirmed its ADI
of0.003 mg/kg, using the NOEL of0.125
mg/kg with a safety factor ofabout 40. The
JMPR, in 1982, evaluated other toxicity
data on aldicarb, primarily reviewing a
dietary study of aldicarb administered in
drinking water, and recommended an
increased ADI of 0.005 mg/kg, maintain-
ing their assessment ofa NOEL but reduc-
ing the margin of uncertainly in their
extrapolation ofanimal data to human risk
(11). In 1983, using a Cornell University
kinetic model, Wilkinson showed that a
safe range for the upper ADI value for
aldicarb and aldicarb metabolites would be
0.003 to 0.01 mg/kg confirming the
JMPR's assessment.
In 1986, with no new toxicological
information but working within the frame-
work provided by the SDWC, the
U.S.EPA's ADI for aldicarb was reduced to
0.001 mg/kg, to conform to technical eval-
uations in various agency offices. In data
from a recent dog study, aldicarb at dose
levels to 0.235 mg/kg displayed no observ-
able adverse effects other than inhibition of
peripheral erythrocyte and plasma acetyl-
cholinesterase activity. The no-effect level
for acetylcholinesterase inhibition was
0.025 mg/kg. In 1990, the ADI was again
reduced to 0.0002 mg/kg presumably as a
result ofthe newest dog study and possibly
as a result of the occurrence of terminal
residues in certain food commodities, for
some ofwhich tolerances had never been
established. In 1992 the JMPR, reviewing
the results of a second human trial and
considering the reported effects of food
containing aldicarb residues, recommended
an ADI of0.003 mg/kg (13). The NOEL
reported for this trial was 0.025 mg/kg.
Cholinesterase Depression as
a Toxicological Basisfor Risk
Assessment
Both organophosphorus and carbamate
insecticides are established inhibitors of
acetylcholinesterase. Since this is the bio-
chemical lesion from which toxicity ulti-
mately results, the measurement of
circulating acetylcholinesterase levels, espe-
cially in blood (plasma and red cell), has
had widespread application as a measure of
human exposure. No active biological
function has ever been defined for any of
the blood acetylcholinesterase isozymes.
Their physiological function in the body is
unknown, although they commonly act as
indicators ofexposure and, subsequently,
as indicators of potential adverse effects.
There are two major types ofenzymes that
hydrolyze acetylcholine. One of these is
acetylcholinesterase ("true" acetylcholinester-
ase) associated with erythrocytes (red cells)
and nervous tissue, and the other is a non-
specific, "pseudo" cholinesterase associated
with blood plasma (or serum) and found in
many other tissues. Acetylcholinesterase
measurements using whole blood include
both erythrocyte and plasma acetylcholin-
esterases activitywith the major contribution
to total activity coming from the erythro-
cyte fraction. These enzymes are generally
separated by differential centrifugation
before assay. Those measurements using
brain tissue also include true and pseudo-
cholinesterase activity and are generally not
differentiated with respect to true or
pseudo- cholinesterase activity except by
substrate specificity. This differentiation is
rare.
Although acetylcholinesterase measure-
ments are undoubtedly valuable in
confirming human or animal exposure to
carbamate or organophosphorus insecti-
cides, Wilkinson (CF Wilkinson, unpub-
lished data) suggested that using them as
indicators ofan "adverse toxic effect" raised
some important questions a) What are the
major problems inherent in measurements
ofacetylcholinesterase activity in individual
animals or populations and what can be
considered normal variation? b) What is
the meaning ofacetylcholinesterase depres-
sion in terms of toxicity and/or the devel-
opment oftoxic symptoms, and how does
it relate to an impairment ofnormal physi-
ologic function? c) Is it possible to establish
a biological threshold of acetylcholin-
esterase inhibition that shows an adverse
toxicological effect? d) Is it proper to use
values ofacetylcholinesterase depression in
setting NOEL and ADI values or for other
regulatory purposes?
Some of these questions have been
addressed recently by the U.S.EPA's
Science Advisory Panel and are undoubt-
edly going to be further considered in
depth by an U.S.EPA Working Group on
Cholinesterase, which recently examined
some of these issues, initially addressing
analytical methodology. The first of these
questions has been discussed in detail by
individuals who have reviewed both inter-
and intraindividual variation in blood
acetylcholinesterase levels (plasma and ery-
throcyte) and experimental error in the
available method. It has been concluded
that, based on observed intraindividual
variations of about 10% (resulting from
unknown physiological, nutritional, or
other factors), a plasma or red cell acetyl-
cholinesterase depression of 15 to 25%
would be considered meaningful based on
a known pre-exposure value. If acetyl-
cholinesterase depression in an individual is
compared with values measured in many
unexposed individuals, the interindividual
variation (15-25% for plasma and 10-15%
for red cell activity) is such that depression
values ofat least 33 and 20%, respectively,
would be needed to show meaningful
decreases in plasma and red cell activities.
The toxicological importance ofacetyl-
cholinesterase inhibition and its relation-
ship to the development of overt signs of
cholinergic poisoning is a complex issue.
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The results differ depending on the type
and location of the acetylcholinesterase
measured and the particular inhibitor in
question. There appear to be few simple
correlations between the inhibition of
plasma, erythrocyte, or brain acetyl-
cholinesterase levels by different com-
pounds. Usually, exposure ofanimals to an
organophosphorus or carbamate insecticide
leads to a rapid decrease in either plasma or
erythrocyte acetylcholinesterase (or both),
but the extent of the inhibition will vary
with the chemical.
There is also evidence suggesting that
the clinical effects of exposure may be
related to the rate of acetylcholinesterase
inhibition, instead of the absolute level of
inhibition. Humans have experienced no
ill effects from repeated low-level occupa-
tional exposure, which gradually reduced
their blood acetylcholinesterase to levels so
low one would have expected severe illness
if the rate of decline had been rapid, as
happens after a single large bolus dose.
Adaptation to decreased levels of acetyl-
cholinesterase may be explained by a physi-
ological adaptation to increased levels of
acetylcholine or by enhanced synthesis of
new enzyme. Industrial workers with 90%
of their blood acetylcholinesterase inhib-
ited have shown no signs or symptoms of
overexposure, while others have been seen
to be severely ill with a similar degree of
acetylcholinesterase inhibition. Con-
sequently, it is extremely difficult to estab-
lish any hard and fast rules on the amount
of peripheral acetylcholinesterase inhibi-
tion that can be expected to lead to toxic
manifestations. Generally, toxic effects are
unlikely to be encountered if the red cell
and plasma acetylcholinesterase activities
stay above 50% of their normal values; a
toxicological threshold of 50% depression
might ultimately be an acceptable value.
In extrapolating from a safe dose level
shown in animals, to an acceptable safe lev-
els for human intake, it is assumed an addi-
tional safety factor should be incorporated
to account for the possibly greater suscepti-
bility ofjuveniles. Very few data are avail-
able to allow meaningful comparisons
between adult and juvenile toxicities of
organophosphorus or carbamate insecti-
cides. One very early report in 1963 of
studies with 15 organophosphorous and
carbamate insecticides showed that wean-
ing rats were more susceptible than adult
animals to cholinergic agents, although the
differences usually were quite small, 12 of
the 16 chemicals tested showed less than a
2-fold increased toxicity to weanings than
to adults, with one chemical actually show-
ing a lower toxicity to weanings than to
adults. In a 1980 report with the carba-
mate insecticide carbofuran, no biologically
meaningful differences between juvenile
and adult rats were observed with respect
to LD50 values, erythrocyte and brain
acetylcholinesterase depression, or the rate
ofonset or recovery from toxic signs (11).
Although the available data do not provide
an adequate basis for any firm conclusions,
they strongly suggest that juvenile animals
may not differ from adults in their suscep-
tibility to cholinergic agents.
Lastly while there is not a large differ-
ence in the general assessment of human
safety (the 25-fold range of0.2-5 pg/kg for
the ADI), the differences in the impact of
the regulatory assessment ofthe ADI have
made an important difference in the com-
mercial life and value ofaldicarb. While we
have seen small differences in the overall
human health assessment, the continuing
erosion ofthe ADI (RfD), the subsequent
reduction of food residue tolerances and
the reduced drinking water advisory levels
has had, and will continue to have, a pro-
found effect of shortening the very
significant commercial agricultural life of
aldicarb.
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